Sonia Biswas, Mariella Toro, Rebecca Horgan, Rodney A McLaren, Vincenzo Berghella, Huda B Al-Kouatly
{"title":"Propranolol to decrease time to delivery: a meta-analysis of randomized controlled trials.","authors":"Sonia Biswas, Mariella Toro, Rebecca Horgan, Rodney A McLaren, Vincenzo Berghella, Huda B Al-Kouatly","doi":"10.1016/j.ajogmf.2025.101705","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the effect of propranolol on the time to delivery among patients undergoing induction or augmentation of labor.</p><p><strong>Data sources: </strong>PubMed, Scopus, Cochrane Library, ClinicalTrials.gov, and CINAHL (EBSCO) databases were searched from inception to December 2023.</p><p><strong>Study eligibility criteria: </strong>Randomized controlled trials that examined the effect of propranolol on the time to delivery among patients undergoing induction or augmentation of labor were included. Randomized controlled trials that included stillbirth before randomization, nonrandomized trials, observational, cohort, case-control, or studies in which the control group included an intervention other than standard care were excluded.</p><p><strong>Methods: </strong>The primary outcome was time to delivery after the administration of propranolol among patients undergoing induction or augmentation of labor. The summary measures were reported as summary mean difference or relative risk with 95% confidence interval.</p><p><strong>Results: </strong>A total of 5 randomized controlled trials involving 660 patients were included in this meta-analysis. 1 study investigated the effect of propranolol compared with that of placebo among patients undergoing induction of labor and did not demonstrate a significant decrease in the time to delivery (828±324 minutes in the propranolol group vs 858±318 minutes in the placebo group; P=.48). In addition, 4 studies investigated the effect of propranolol among patients undergoing augmentation of labor and showed no significant decrease in the time to delivery (mean difference, -2.98 minutes [95% confidence interval, -21.6 to 15.6]). Our pooled analysis demonstrated that the use of propranolol in the induction and augmentation of labor was not associated with a decrease in the time to delivery from the administration of propranolol compared with that of placebo (mean difference, -4.33 minutes [95% confidence interval, -22.48 to 13.83]). The meta-analysis found no increased risk of postpartum hemorrhage, blood transfusion, cesarean delivery rate, or neonatal intensive care unit admission with the use of propranolol during labor.</p><p><strong>Conclusion: </strong>The use of propranolol during induction and augmentation of labor did not significantly decrease the time to delivery.</p>","PeriodicalId":36186,"journal":{"name":"American Journal of Obstetrics & Gynecology Mfm","volume":" ","pages":"101705"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Obstetrics & Gynecology Mfm","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajogmf.2025.101705","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to assess the effect of propranolol on the time to delivery among patients undergoing induction or augmentation of labor.
Data sources: PubMed, Scopus, Cochrane Library, ClinicalTrials.gov, and CINAHL (EBSCO) databases were searched from inception to December 2023.
Study eligibility criteria: Randomized controlled trials that examined the effect of propranolol on the time to delivery among patients undergoing induction or augmentation of labor were included. Randomized controlled trials that included stillbirth before randomization, nonrandomized trials, observational, cohort, case-control, or studies in which the control group included an intervention other than standard care were excluded.
Methods: The primary outcome was time to delivery after the administration of propranolol among patients undergoing induction or augmentation of labor. The summary measures were reported as summary mean difference or relative risk with 95% confidence interval.
Results: A total of 5 randomized controlled trials involving 660 patients were included in this meta-analysis. 1 study investigated the effect of propranolol compared with that of placebo among patients undergoing induction of labor and did not demonstrate a significant decrease in the time to delivery (828±324 minutes in the propranolol group vs 858±318 minutes in the placebo group; P=.48). In addition, 4 studies investigated the effect of propranolol among patients undergoing augmentation of labor and showed no significant decrease in the time to delivery (mean difference, -2.98 minutes [95% confidence interval, -21.6 to 15.6]). Our pooled analysis demonstrated that the use of propranolol in the induction and augmentation of labor was not associated with a decrease in the time to delivery from the administration of propranolol compared with that of placebo (mean difference, -4.33 minutes [95% confidence interval, -22.48 to 13.83]). The meta-analysis found no increased risk of postpartum hemorrhage, blood transfusion, cesarean delivery rate, or neonatal intensive care unit admission with the use of propranolol during labor.
Conclusion: The use of propranolol during induction and augmentation of labor did not significantly decrease the time to delivery.
期刊介绍：
The American Journal of Obstetrics and Gynecology (AJOG) is a highly esteemed publication with two companion titles. One of these is the American Journal of Obstetrics and Gynecology Maternal-Fetal Medicine (AJOG MFM), which is dedicated to the latest research in the field of maternal-fetal medicine, specifically concerning high-risk pregnancies. The journal encompasses a wide range of topics, including:
Maternal Complications: It addresses significant studies that have the potential to change clinical practice regarding complications faced by pregnant women.
Fetal Complications: The journal covers prenatal diagnosis, ultrasound, and genetic issues related to the fetus, providing insights into the management and care of fetal health.
Prenatal Care: It discusses the best practices in prenatal care to ensure the health and well-being of both the mother and the unborn child.
Intrapartum Care: It provides guidance on the care provided during the childbirth process, which is critical for the safety of both mother and baby.
Postpartum Issues: The journal also tackles issues that arise after childbirth, focusing on the postpartum period and its implications for maternal health. AJOG MFM serves as a reliable forum for peer-reviewed research, with a preference for randomized trials and meta-analyses. The goal is to equip researchers and clinicians with the most current information and evidence-based strategies to effectively manage high-risk pregnancies and to provide the best possible care for mothers and their unborn children.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
